Skip to content
Virazole, Rebetol(ribavirin)
Rebetol, Virazole (ribavirin) is a small molecule pharmaceutical. Ribavirin was first approved as Virazole on 1985-12-31. It is used to treat chronic hepatitis c, human adenovirus infections, respiratory syncytial virus infections, virus diseases, and west nile fever in the USA. It has been approved in Europe to treat chronic hepatitis c. The pharmaceutical is active against inosine-5'-monophosphate dehydrogenase 2 and inosine-5'-monophosphate dehydrogenase 1.
Download report
Favorite
COVID-19
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Virazole (generic drugs available since 2005-10-28, discontinued: Copegus, Rebetol, Ribasphere)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ribavirin
Tradename
Company
Number
Date
Products
VIRAZOLEBausch Health CompaniesN-018859 RX1985-12-31
1 products, RLD, RS
Show 3 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
virazoleNew Drug Application2019-05-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
chronic hepatitis cEFO_0004220D019698B18.2
human adenovirus infectionsEFO_0007434D000258
respiratory syncytial virus infectionsEFO_1001413D018357
virus diseasesD014777B34
west nile feverEFO_0007545D014901A92.3
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Ribavirin, Rebetol, Schering
67908372023-04-05DP
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AP: Antivirals for treatment of hcv infections
J05AP01: Ribavirin
HCPCS
No data
Clinical
Clinical Trials
736 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic hepatitis cD019698EFO_0004220B18.2141111078170370
Hepatitis cD006526B19.2882634435219
Hiv infectionsD015658EFO_0000764B20101999549
HepacivirusD01617417145739
Chronic hepatitis bD019694EFO_0004197B18.1116202138
Liver cirrhosisD008103EFO_0001422K74.05153222
Hepatitis bD0065091451413
HivD006678O98.71125211
HepatitisD006505HP_0012115K75.9143119
Liver diseasesD008107EFO_0001421K70-K773317
Show 24 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Covid-19D000086382U07.124218
FibrosisD0053551326
InfectionsD007239EFO_00005441315
Chronic hepatitisD006521K73.9213
RecurrenceD0120081123
PneumoniaD011014EFO_0003106J182113
Experimental liver cirrhosisD008106212
Respiratory syncytial virus infectionsD018357EFO_1001413112
Renal insufficiencyD051437HP_0000083N1911
MenopauseD008593EFO_0003922N9511
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.0244
Lassa feverD007835EFO_0007338A96.2213
ThrombocytopeniaD013921HP_0001873D69.622
Hemorrhagic fever with renal syndromeD006480EFO_0007299A98.522
PharmacokineticsD01059911
Treatment failureD01721111
Chronic painD059350HP_001253211
Human influenzaD007251EFO_0007328J11.111
Hepatocellular carcinomaD006528C22.011
Severe dengueD019595A9111
Show 11 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients66
Head and neck neoplasmsD006258112
Hepatic insufficiencyD04855011
Squamous cell neoplasmsD01830711
Follicular lymphomaD008224C8211
Mantle-cell lymphomaD020522C83.111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Intravenous substance abuseD01581911
MelanomaD00854511
Medication adherenceD055118EFO_000634411
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8111
Chronic fatigue syndromeD015673EFO_0004540G93.3111
Major depressive disorderD003865EFO_0003761F2211
Cognition disordersD00307211
Respiratory distress syndromeD012128EFO_1000637J8011
Viral hemorrhagic feversD006482A9911
Lichen planusD008010L4311
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRIBAVIRIN
INNribavirin
Description
Ribavirin is a white powder and exists in two polymorphic forms. Ribavirin is a 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. It has a role as an antimetabolite, an antiviral agent, an antiinfective agent and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is a 1-ribosyltriazole, an aromatic amide and a monocarboxylic acid amide. Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA, thereby inhibiting viral RNA synthesis, inducing viral genome mutations, and inhibiting normal viral replication.
Classification
Small molecule
Drug classantivirals
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
Identifiers
PDB3SFU
CAS-ID36791-04-5
RxCUI9344
ChEMBL IDCHEMBL1643
ChEBI ID63580
PubChem CID37542
DrugBankDB00811
UNII ID49717AWG6K (ChemIDplus, GSRS)
Target
Agency Approved
IMPDH2
IMPDH2
IMPDH1
IMPDH1
Organism
Homo sapiens
Gene name
IMPDH2
Gene synonyms
IMPD2
NCBI Gene ID
Protein name
inosine-5'-monophosphate dehydrogenase 2
Protein synonyms
epididymis secretory sperm binding protein, IMP (inosine 5'-monophosphate) dehydrogenase 2, IMP (inosine monophosphate) dehydrogenase 2, IMP dehydrogenase II, IMP oxireductase 2, IMPD 2, IMPDH 2, IMPDH-II, inosine 5' phosphate dehydrogenase 2, inosine monophosphate dehydrogenase type II, Inosine-5'-monophosphate dehydrogenase type II
Uniprot ID
Mouse ortholog
Impdh2 (23918)
inosine-5'-monophosphate dehydrogenase 2 (Q91Z11)
Alternate
No data
Variants
Clinical Variant
Identifier
Target mutation
Effect
Evaluation
Status
VCV000225949IFNL4, 151-152G>Adrug response2021-03-241A
VCV000226027IFNL3drug response2021-03-291B
VCV000375658IFNL3, 259-126T>Cdrug response2021-03-242A
VCV000014747ITPA, 124+21A>Cdrug response2021-03-242B
VCV000014746ITPA, 94C>A, Pro32Thrdrug response2021-03-242B
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 31,133 documents
View more details
Safety
Black-box Warning
Black-box warning for: Virazole
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
391 adverse events reported
View more details